Developing First-in-Class Dual Inhibitors Targeting Both BET Bromodomains and Dopamine Receptor 2 for the Treatment of Rare Diseases © 2017 ConverGene LLC, All Rights Reserved.

ConverGene is a small molecule discovery company leveraging rational drug design. Our mission is to develop therapeutics with novel mechanisms of action for cancer patients with limited or no treatment …

Jan 11, 2017 · ConverGene Advances NCATS Collaboration, Biocentury Article. ConverGene entered into an exclusive license agreement with the National Center for Advancing Translational Sciences …

Makoto Yoshioka, Ph.D. VP of Research Dr. Yoshioka currently serves as VP of Research for ConverGene. He is currently heading optimization work for the Company’s lead compounds.

Product Development Pipeline Available to Partner or License Pipeline for Internal Development © 2017 ConverGene LLC, All Rights Reserved.

Request ConverGene's Non-Confidential Slide Deck Sign in to Google to save your progress. Learn more

Apr 6, 2017 · ConverGene (www.convergenepharma.com) is a small molecule discovery company leveraging rational drug design. Our mission is to develop therapeutics with novel mechanisms of …

CG223 is “affinity tunable” with 2 distinct sites for binding of BET bromo-domain proteins and DRD2. This unique dual mechanism of action is first-in-class. The distinct chemical structure of our drug has …

Jan 25, 2017 · ConverGene Announces Sponsored Research Agreement 3791343 news, Uncategorized Jan 25, 2017

Sep 18, 2017 · Dr. Jeff Strovel, PhD, President and CEO of ConverGene, commented, “We are very excited to kickoff this study with MD Anderson. Our first-in-class cancer drug candidates will be …